Female Sexual Health — Cost, Top Hospitals & Success Rates | MyMedicPlus

Female sexual health encompasses the physical, emotional, mental, and social wellbeing of women in relation to sexuality—not merely the absence of dysfunction. Female sexual dysfunction (FSD) is a common, underdiagnosed, and often undertreated condition affecting approximately 43% of adult women to some degree, with significant distress and quality-of-life impact. The spectrum of FSD includes hypoactive sexual desire disorder (HSDD—reduced or absent sexual desire causing personal distress), female sexual arousal disorder, genito-pelvic pain/penetration disorder (GPPPD—incorporating dyspareunia and vaginismus), and orgasmic disorder.

The biopsychosocial model underpins modern sexual medicine: FSD results from the complex interplay of biological factors (hormonal changes, medical conditions, medications), psychological factors (anxiety, depression, trauma, relationship satisfaction, body image), and social and relational factors (partner issues, cultural beliefs, past trauma). Effective treatment therefore requires a holistic, multidisciplinary assessment addressing all domains. A sexual medicine specialist, gynaecologist, sex therapist, pelvic floor physiotherapist, and psychologist may all contribute to a comprehensive management plan.

Patient assessment includes detailed sexual history (sensitive, non-judgemental), general medical history focusing on hormonal status (menopausal symptoms, thyroid, prolactin), medications (antidepressants, antihypertensives, oral contraceptives as common contributors), mental health history, and relationship context. Physical examination assesses vulval and vaginal health, pelvic floor function, and signs of atrophy. Validated questionnaires (Female Sexual Function Index—FSFI, Female Sexual Distress Scale—FSDS) quantify dysfunction and guide treatment response monitoring.

Hypoactive sexual desire disorder (HSDD)—the most common FSD, affecting 10–15% of women—is characterised by absent or reduced sexual desire causing personal distress. Biological contributors include declining androgen levels (particularly in surgical menopause), antidepressant use (SSRIs notably suppress libido), and chronic medical illness. Treatment includes addressing reversible pharmacological causes, optimising menopausal hormone therapy, and psychosexual therapy.

Genitopelvic pain/penetration disorder (GPPPD) encompasses dyspareunia (painful intercourse) from superficial causes (vulvodynia, vestibulodynia, lichen sclerosus, vaginal atrophy) and deep causes (endometriosis, pelvic inflammatory disease, ovarian cysts), and vaginismus (involuntary pelvic floor muscle spasm preventing penetration). Genitourinary syndrome of menopause (GSM—vaginal atrophy, dryness, pain) affects up to 60% of postmenopausal women and is highly responsive to topical oestrogen. Provoked vestibulodynia—localised vulval hypersensitivity causing severe entry dyspareunia—requires a specialised multidisciplinary approach combining pelvic floor physiotherapy, topical treatments, and psychosexual therapy.

Any woman experiencing sexual dysfunction that causes personal distress is eligible for assessment and treatment. There are no age restrictions—FSD affects women from adolescence to elderly age, with different dominant presentations at different life stages. Younger women frequently present with vaginismus or provoked vestibulodynia. Midlife women experience hormonal transitions affecting desire and arousal. Post-menopausal women commonly present with GSM-related pain and reduced desire. Women following cancer treatment—particularly breast cancer patients on anti-oestrogen therapy—experience severe sexual side effects requiring specialist management.

Contraindications to specific treatments vary: systemic hormone replacement therapy (HRT) for GSM is contraindicated in women with oestrogen-sensitive breast cancer (topical vaginal oestrogen at low doses is usually safe with oncologist approval). Testosterone therapy for HSDD is not FDA-approved in women in the US but is widely used off-label. Flibanserin (Addyi), FDA-approved for pre-menopausal HSDD, is contraindicated with alcohol consumption and strong CYP3A4 inhibitors. Bremelanotide (Vyleesi, melanocortin receptor agonist) is contraindicated in cardiovascular disease.

Psychosexual therapy (cognitive-behavioural sex therapy, sensate focus exercises, mindfulness-based approaches) is the most evidence-based treatment for FSD across all subtypes and should be offered or combined with all pharmacological treatments. It addresses negative beliefs about sex, performance anxiety, relationship conflict, communication difficulties, and trauma. Couple therapy or individual therapy is offered depending on the clinical presentation.

Hormonal treatments include local vaginal oestrogen (cream, pessary, tablet, ring) for GSM—highly effective, with minimal systemic absorption making it safe for most women including many breast cancer patients with specialist approval. Systemic HRT (oestrogen with or without progestogen) addresses GSM and also improves libido in perimenopausal women by restoring hormonal milieu. Off-label testosterone therapy (lower doses than male therapy) improves HSDD in post-menopausal women—evidence from multiple RCTs shows significant improvement in satisfying sexual events and desire. Flibanserin (Addyi) 100 mg at bedtime is FDA-approved for pre-menopausal HSDD, with modest benefit (1–2 additional satisfying sexual events per month versus placebo). Pelvic floor physiotherapy with vaginal dilator training is highly effective for vaginismus and provoked vestibulodynia, achieving resolution in 70–80% of compliant patients. Botulinum toxin injection into the pelvic floor is an emerging treatment for severe vaginismus. Shared decision-making between the patient and specialist ensures the chosen modality aligns with individual anatomy, comorbidities, risk tolerance, and personal goals. A formal consultation with a board-certified specialist, review of pre-treatment imaging or investigation results, and multidisciplinary team input for complex cases are standard practice before finalising the treatment plan.

Treatment of GSM with topical oestrogen resolves vaginal dryness and dyspareunia in 80–90% of women within 4–8 weeks of regular use. Consistent long-term use maintains mucosal health and prevents recurrence. Testosterone therapy in post-menopausal HSDD achieves clinically meaningful improvements in desire, arousal, and satisfying sexual events—a large meta-analysis (Davis et al., Lancet Diabetes & Endocrinology 2019) demonstrates significant benefit across multiple outcomes.

Pelvic floor physiotherapy for vaginismus achieves full penetration capability in 70–90% of women who complete the treatment programme, often transforming quality of life and relationship functioning. Psychosexual therapy for FSD broadly achieves significant functional improvement in desire, arousal, and satisfaction in 60–75% of patients, with benefits extending to relationship quality. Combined pharmacological and psychological treatment consistently outperforms either modality alone.

Topical vaginal oestrogen is safe with minimal systemic absorption; slight vaginal irritation may occur initially. Systemic HRT carries small but real risks of breast cancer (combined oestrogen-progestogen HRT), venous thromboembolism (oral but not transdermal oestrogen), and stroke, which must be individualised against benefits. Testosterone therapy in women at appropriate doses is safe in short-to-medium-term trials (up to 2 years); longer-term safety data are still accumulating; acne and mild hirsutism occur in a minority.

Flibanserin is associated with dizziness, somnolence, and hypotension—particularly when combined with alcohol (absolute contraindication) or CYP3A4 inhibitors. Psychosexual therapy may transiently increase distress as difficult emotions are explored, but is managed within the therapeutic relationship. Vaginal dilator training can initially cause discomfort, which is addressed by gradual, self-paced progression guided by the pelvic floor physiotherapist.

Women commencing treatment for FSD are reviewed at 6–8 weeks to assess initial response, tolerability, and engagement with psychosexual therapy. Validated outcome measures (FSFI, FSDS) at each review allow quantification of improvement and guide treatment adjustment. Hormonal therapies require ongoing review with attention to systemic effects; testosterone levels should be monitored to remain within female physiological range.

Pelvic floor physiotherapy is reviewed every 4–6 sessions, with progress documented by dilator tolerance and pelvic floor assessment. Most women complete a full programme in 3–6 months. Post-treatment review at 6 and 12 months assesses sustained improvement and need for maintenance therapy. Women with FSD related to chronic conditions (menopause, cancer treatment, chronic pain) often benefit from long-term specialist follow-up and access to a dedicated sexual medicine clinic.

In the United States, sexual medicine consultations cost USD 200–400 per session. Pelvic floor physiotherapy costs USD 100–200 per session, with typical programmes of 8–12 sessions. Flibanserin costs approximately USD 400–800 per month without insurance. Vaginal oestrogen preparations cost USD 30–150 per month. Psychosexual therapy costs USD 150–300 per session, with most programmes lasting 8–16 sessions.

In India, gynaecology and sexual medicine consultations cost USD 10–30 at leading hospitals. Pelvic floor physiotherapy is available at specialist women's health physiotherapy centres for USD 20–50 per session. Vaginal oestrogen preparations are available at USD 5–20 per month. Testosterone preparations for women are available off-label at low cost in India and many Asian countries. Comprehensive sexual medicine assessment and therapy is available at Apollo, Fortis, and AIIMS at a fraction of Western prices, making India an attractive option for international patients requiring specialist gynaecological and psychosexual care.

For GSM, non-hormonal vaginal moisturisers (Replens, Yes Organics) and lubricants provide symptomatic relief from dryness without hormonal risk, though they do not address the underlying atrophy. Ospemifene (selective oestrogen receptor modulator) is an oral non-hormonal tablet approved for moderate-to-severe dyspareunia from GSM, representing a systemic non-oestrogen alternative. Laser vaginal rejuvenation (fractional CO2 or Er:YAG laser applied intravaginally) is an emerging non-hormonal treatment for GSM showing promising outcomes in pilot studies, though long-term evidence is limited.

Acupuncture, mindfulness-based stress reduction, and yoga have emerging evidence for improving sexual function and reducing sexual distress through stress reduction and body awareness mechanisms. Cognitive-behavioural therapy (CBT) alone is effective for FSD in the absence of hormonal contributors. Relationship therapy or couples counselling is often the most impactful intervention when relationship conflict or communication difficulties are the dominant factor underlying FSD.